Showing results (41-50 of 45) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Blood Advances|December 23, 2021
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphomaAnn-Marie E Bröske, Koorosh Korfi, Anton Belousov, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II StudyTycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancerJ-C Soria, A Fülöp, C Maciel, et al.JAMA|May 12, 2017
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical TrialPasi A Jänne, Michel M van den Heuvel, Fabrice Barlesi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2021
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I TrialMartin Hutchings, Franck Morschhauser, Gloria Iacoboni, et al.Pageof 5